ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome
24. Juli 2024 10:00 ET
|
ConSynance Therapeutics
FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
06. Juni 2024 09:00 ET
|
Tiziana Life Sciences Ltd.
Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months.FDA...
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
04. Juni 2024 09:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
13. Mai 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Imbria Pharmaceuticals to Present Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at American College of Cardiology Annual Scientific Session & Expo (ACC.24)
25. März 2024 08:00 ET
|
Imbria Pharmaceuticals Inc.
– Ninerafaxstat Phase 2 clinical trial in non-obstructive hypertrophic cardiomyopathy (nHCM) is complete;Phase 3 to be initiated in the 2H 2024 – BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Imbria...
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
13. März 2024 07:55 ET
|
Catalyst Pharmaceuticals, Inc.
AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for...
US Rare Disease Drug Market Drugs Sales Clinical Trials Insight
25. Juli 2023 03:12 ET
|
KuicK Research
Delhi, July 25, 2023 (GLOBE NEWSWIRE) -- US Orphan Drugs Market, Drugs Sales, Price, Dosage & Clinical Trials Insight 2028 Report Highlights: US Orphan Drugs Market Opportunity: > USD...
ConSynance Therapeutics Reports Positive Phase 1 Results for CSTI-500 in Prader-Willi Syndrome Patients
30. Mai 2023 10:00 ET
|
ConSynance Therapeutics
RENSSELAER, New York, May 30, 2023 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., an emerging biopharmaceutical firm focused on developing novel therapies for rare central nervous system (CNS)...
QSAM Biosciences Receives Rare Pediatric Disease Designation from FDA for CycloSam in the Treatment of Osteosarcoma
02. Februar 2022 08:30 ET
|
QSAM Biosciences Inc.
Austin, TX, Feb. 02, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
Follow one woman as she embarks on a journey of self-discovery in ‘The Royal Orphan’
11. März 2021 01:39 ET
|
Archway Publishing
GRABILL, Ind., March 11, 2021 (GLOBE NEWSWIRE) -- An 18-year-old orphan comes to work for her kingdom’s royal family and soon finds romance, personal growth and tragedy in Lanelle Thomas’ new...